Compare Adaptive Biotechnologies Corp (ADPT) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Riot Platforms Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Riot Platforms Inc trades at $20.96 (market cap $8.01B). The key difference: Riot Platforms Inc is far larger — about 2.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | RIOT | |
|---|---|---|
Market Cap | $3.33B | $8.01B |
Sector | Health | Technology |
52-Week High | $22.37 | $28.67 |
52-Week Low | $10.24 | $11.03 |
Enterprise Value | $3.19B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
RIOT trades at $22.87, up 3.44% today, but technical indicators signal a bearish trend with resistance at $24. The company reported a net loss of $663.18 million in 2025 with negative cash flow from operations, though revenue reached $647.44 million. Recent news highlights volatility tied to Bitcoin price swings and a strategic pivot toward high-performance computing data centers, including a partnership with Terrestrial Energy for nuclear-powered facilities.
Wall Street analysts remain overwhelmingly bullish with a 94% buy rating and $27.83 consensus price target, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI data center strategy amid competitive and regulatory pressures in the energy-intensive mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
